These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 34273083

  • 1. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
    [Abstract] [Full Text] [Related]

  • 2. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
    Araujo-Castro M, Hanzu FA, Pascual-Corrales E, García Cano AM, Marchan M, Escobar-Morreale HF, Valderrabano P, Casals G.
    Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
    [Abstract] [Full Text] [Related]

  • 3. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
    [Abstract] [Full Text] [Related]

  • 4. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
    Araujo-Castro M, Parra Ramírez P, Martín Rojas-Marcos P, García Centeno R, Gracia Gimeno P, Tomé Fernández-Ladreda M, Sampedro Núñez MA, Higueruela C, Robles Lázaro C.
    Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
    [Abstract] [Full Text] [Related]

  • 5. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M, García Cano AM, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
    [Abstract] [Full Text] [Related]

  • 6. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, Cuesta Hernández M, Sampedro Núñez MA, Marazuela M.
    Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion.
    Araujo-Castro M, García Cano A, Jiménez Mendiguchía L, Escobar-Morreale HF, Valderrábano P.
    Sci Rep; 2021 Oct 15; 11(1):20539. PubMed ID: 34654835
    [Abstract] [Full Text] [Related]

  • 8. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
    Patrova J, Kjellman M, Wahrenberg H, Falhammar H.
    Endocrine; 2017 Nov 15; 58(2):267-275. PubMed ID: 28887710
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases.
    Brox-Torrecilla N, García Cano AM, Valderrábano P, Quintero Tobar A, Escobar-Morreale HF, Araujo-Castro M.
    Endocrine; 2023 Sep 15; 81(3):484-491. PubMed ID: 37212980
    [Abstract] [Full Text] [Related]

  • 13. Performance of DHEAS as a Screening Test for Autonomous Cortisol Secretion in Adrenal Incidentalomas: A Prospective Study.
    Liu MS, Lou Y, Chen H, Wang YJ, Zhang ZW, Li P, Zhu DL.
    J Clin Endocrinol Metab; 2022 Apr 19; 107(5):e1789-e1796. PubMed ID: 35137142
    [Abstract] [Full Text] [Related]

  • 14. Relationship Between Dexamethasone Suppression Test Cortisol Level >0.9 μg/dL and Depression and Quality of Life in Adrenal Incidentalomas: A Single Center Observational Case-Control Study.
    Güneş M, Güneş E, Kaya Mİ, Küçükelyas HD, Barut H, Öner S.
    Endocr Pract; 2024 Aug 19; 30(8):710-717. PubMed ID: 38729569
    [Abstract] [Full Text] [Related]

  • 15. The degree of cortisol secretion is associated with diabetes mellitus and hypertension in patients with nonfunctioning adrenal tumors.
    Favero V, Aresta C, Parazzoli C, Cairoli E, Eller-Vainicher C, Palmieri S, Salcuni AS, Arosio M, Persani L, Scillitani A, Morelli V, Chiodini I.
    Cardiovasc Diabetol; 2023 May 02; 22(1):102. PubMed ID: 37131218
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Saliva versus serum cortisol to identify subclinical hypercortisolism in adrenal incidentalomas: simplicity versus accuracy.
    Vieira-Correa M, Giorgi RB, Oliveira KC, Hayashi LF, Costa-Barbosa FA, Kater CE.
    J Endocrinol Invest; 2019 Dec 02; 42(12):1435-1442. PubMed ID: 31456173
    [Abstract] [Full Text] [Related]

  • 18. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM.
    Eur J Endocrinol; 2023 Jul 20; 189(1):G1-G42. PubMed ID: 37318239
    [Abstract] [Full Text] [Related]

  • 19. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C, Tonacchera M.
    Endocrine; 2021 Jan 20; 71(1):178-188. PubMed ID: 32915435
    [Abstract] [Full Text] [Related]

  • 20. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
    Araujo-Castro M, Mínguez Ojeda C, Sánchez Ramírez MN, Gómez Dos Santos V, Pascual-Corrrales E, Fernández-Argüeso M.
    Endocrine; 2022 Oct 20; 78(1):142-150. PubMed ID: 35751779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.